|
Bispecific Antibodies market to be worth USD 4.4 billion by 2023, predicts …
Fort Mills Times Roots Analysis has announced addition of the “Bispecific Antibody Therapeutics Market, 2013-2023” report to their offering. The report provides an extensive study of this emerging field, including detailed sales forecast of molecules undergoing … |
|
Bispecific Antibodies market to be worth USD 4.4 billion by 2023, predicts …
4-traders (press release) Roots Analysis has announced addition of the “Bispecific Antibody Therapeutics Market, 2013-2023” report to their offering. The report provides an extensive study of this emerging field, including detailed sales forecast of molecules undergoing … |
Recommendations help physicians in treating systemic juvenile arthritisToronto NewsFIX… the use of Non-steroidal anti-inflammatory drugs (NSAIDs), Glucocorticoids, Methotrexate, Leflunomide, Intravenous immunoglobulin (IVIG), Calcineurin inhibitors, …
Clinical Oncology NewsDose-Dense Regimen Does Not Improve R-CHOP for DLBCLClinical Oncology NewsThe addition of rituximab (Rituxan, Genentech) to the regimen (i.e., R-CHOP) was found to improve cure rates by 10% to 15%. Researchers from the United King…
|
OncoMed Pharmaceuticals (OMED) Early-Stage Cancer Antibodies Could Raise …
The Wall Street Transcript “[OncoMed] was a recent IPO this year, and this company is also an antibody-development company or a biotherapeutic company, and they are developing cancer antibodies, and they presently have five early-stage cancer antibodies that are wholly owned … |
|
TSH receptor antibodies could affect BMD loss in postmenopausal women
Healio Whole body and lumbar spine bone mineral density z scores were significantly lower among long-term euthyroid postmenopausal women with treated Graves’ disease compared with controls, according to data published in Thyroid Research. The data also … |
Inovio Pharma (INO) Reports Publication of DNA Plasmid Tech in Generating …StreetInsider.com (subscription)Inovio Pharmaceuticals, Inc. (AMEX: INO) announced the publication of a peer-reviewed paper demonstrating the success of its new DNA plasmid te…
Paid Rheumatoid Arthritis (RA) Clinical Trial Now Enrolling at Achieve …PR Web (press release)Achieve is conducting a study to evaluate the safety and efficacy of a new drug versus rituximab in patients with moderately to severely active rheumatoid a…
Telegraph.co.ukPersistence of bactericidal antibodies following early infant vaccination with …CMAJBackground: The multicomponent serogroup B men in gococcal (4CMenB) vaccine was recently licensed for use in Europe. There are currently no data on the…
|
BioLineRx Ltd.’s BL-8040 Receives Orphan Drug Designation for Treatment of …
Lifescience-online Pre-clinical studies show that BL-8040 is efficient, both alone and in combination with the anti-cancer drug Rituximab, in reducing bone marrow metastasis of lymphoma cells and stimulating lymphoma cell death. BL-8040 was licensed by BioLineRx from … |